ADAM22 as a prognostic and therapeutic drug target in the treatment of endocrine-resistant breast cancer

Vitamins and Hormones

Volumn 93, Issue , 2013, Pages 307-321

  Bolger, Jarlath C ^a   Young, Leonie S ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

ADAM22; Endocrine resistance; LGI1; SRC 1

Indexed keywords

EID: 84880313733     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-416673-8.00014-9     Document Type: Chapter

References (42)

1. Blobel C.P., Wolfsberg T.G., Turck C.W., Myles D.G., Primakoff P., White J.M. A potential fusion peptide and an integrin ligand domain in a protein active in sperm-egg fusion. Nature 1992, 356:248-252.
2. Bonnefoy-Bérard N., Liu Y.C., von Willebrand M., Sung A., Elly C., Mustelin T., et al. Inhibition of phosphatidylinositol 3-kinase activity by association with 14-3-3 proteins in T cells. Proceedings of the National Academy of Sciences United States of America 1995, 92(22):10142-10146.
3. Cao Y., Kang Q., Zolkiewska A. Metalloprotease-disintegrin ADAM 12 interacts with alpha-actinin-1. The Biochemical Journal 2001, 357(Pt 2):353-361.
4. Cesi V., Casciati A., Sesti F., Tanno B., Calabretta B., Raschellà G. TGFβ-induced c-Myb affects the expression of EMT-associated genes and promotes invasion of ER+ breast cancer cells. Cell Cycle 2011, 10(23):4149-4161.
5. Deuss M., Reiss K., Hartmann D. Part-time α-secretases: The functional biology of ADAM 9, 10 and 17. Current Alzheimer Research 2008, 5:187-201.
6. Duffy M.J., Mullooly M., O'Donovan N., Sukor S., Crown J., Pierce A., et al. The ADAMs family of proteases: New biomarkers and therapeutic targets for cancer?. Clinical Proteomics 2011, 9:8-9.
7. Dyczynska E., Sun D., Yi H., Sehara-Fujisawa A., Blobel C.P., Zolkiewska A. Proteolytic processing of delta-like 1 by ADAM proteases. The Journal of Biological Chemistry 2007, 282(1):436-444.
8. Edwards D.R., Handsley M.M., Pennington C.J. The ADAM metalloproteinases. Molecular Aspects of Medicine 2008, 29:258-259.
9. Fanger G.R., Widmann C., Porter A.C., Sather S., Johnson G.L., Vaillancourt R.R., et al. 14-3-3 proteins interact with specific MEK kinases. Journal of Biological Chemistry 1998, 273(6):3476-3483.
10. Fridman J.S., Caulder E., Hansbury M., Liu X., Yang G., Wang Q., et al. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clinical Cancer Research 2007, 13(6):1892-1902.
11. Fry J.L., Toker A. Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration. Cancer Research 2010, 70(20):8187-8198.
12. Fukata Y., Adesnik H., Iwanaga T., Bredt D.S., Nicoll R.A., Fukata M. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. Science 2006, 313(5794):1792-1795.
13. Gabellini N., Masola V. Expression of LGI1 impairs proliferation and survival of HeLa cells. International Journal of Cell Biology 2009, 2009:417197.
14. Gabellini N., Masola V., Quartesan S., Oselladore B., Nobile C., Michelucci R., et al. Increased expression of LGI1 gene triggers growth inhibition and apoptosis of neuroblastoma cells. Journal of Cellular Physiology 2006, 207:711-721.
15. Gaultier A., Cousin H., Alfandari D., White J.M. ADAM13 disintegrin and cysteine-rich domains bind to the second heparin-binding domain of fibronectin. The Journal of Biological Chemistry 2002, 277:23336-23344.
16. Gilpin B.J., Loechel F., Mattei M.G., Engvall E., Albrechtsen R., Wewer U.M. A novel secreted form of human ADAM12 (Meltrin a) provokes myogenesis in vivo. The Journal of Biological Chemistry 1998, 273:157-166.
17. Izumi Y., Hirata M., Hasuwa H., Iwamoto R., Umata T., Miyado K., et al. A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. The EMBO Journal 1998, 17(24):7260-7272.
18. Jones D.H., Ley S., Aitken A. Isoforms of 14-3-3 protein can form homo- and heterodimers in vivo and in vitro: Implications for function as adapter proteins. FEBS Letters 1995, 368:55-58.
19. Kenny P.A., Bissell M.J. Targeting TACE-dependent EGFR ligand shedding in breast cancer. The Journal of Clinical Investigation 2007, 117(2):337-345.
20. Knopfová L., Beneš P., Pekarčíková L., Hermanová M., Masařík M., Pernicová Z., et al. c-Myb regulates matrix metalloproteinases 1/9, and cathepsin D: Implications for matrix-dependent breast cancer cell invasion and metastasis. Molecular Cancer 2012, 11:15.
21. Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K. LGI1, a putative tumour metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinase in glioma cells through the ERK1/2 pathway. The Journal of Biological Chemistry 2004, 279:23151-23157.
22. Kveiborg M., Albrechtsen R., Couchman J.R., Wewer U.M. Cellular roles of ADAM12 in health and disease. The International Journal of Biochemistry & Cell Biology 2008, 40(9):1685-1702.
23. Liu H., Shim A.H., He X. Structural characterization of the ectodomain of a disintegrin and metalloproteinase-22 (ADAM22), a neural adhesion receptor instead of metalloproteinase: Insights on ADAM function. The Journal of Biological Chemistry 2009, 284(42):29077-29086.
24. McBryan J., Theissen S.M., Byrne C., Hughes E., Cocchiglia S., Sande S., et al. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. Cancer Research 2012, 72(2):548-559.
25. McCartan D., Bolger J.C., Fagan A., Byrne C., Hao Y., Qin L., et al. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer. Cancer Research 2012, 72(1):220-229.
26. McGowan P.M., McKiernan E., Bolster F., Ryan B.M., Hill A.D., McDermott E.W., et al. ADAM-17 predicts adverse outcome in patients with breast cancer. Annals of Oncology 2008, 19(6):1075-1081.
27. McPherson R.A., Harding A., Roy S., Lane A., Hancock J.F. Interactions of c-Raf-1 with phosphatidylserine and 14-3-3. Oncogene 1999, 18(26):3862-3869.
28. Murphy G. The ADAMs: Signalling scissors in the tumour microenvironment. Nature Reviews. Cancer 2008, 8(12):929-941.
29. O'Shea C., McKie N., Buggy Y., Duggan C., Hill A.D., McDermott E., et al. Expression of ADAM-9 mRNA and protein in human breast cancer. International Journal of Cancer 2003, 105(6):754-761.
30. Parkin E., Harris B. A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10. Journal of Neurochemistry 2009, 108(6):1464-1479.
31. Powell R.M., Wicks J., Holloway J.W., Holgate S.T., Davies D.E. The splicing and fate of ADAM33 transcripts in primary human airway fibroblasts. American Journal of Respiratory Cell and Molecular Biology 2004, 31:13-21.
32. Redmond A.M., Bane F.T., Stafford A.T., McIlroy M., Dillon M.F., Crotty T.B., et al. Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clinical Cancer Research 2009, 15(6):2098-2106.
33. Sagane K., Hayakawa K., Kai J., Hirohashi T., Takahashi E., Miyamoto N., et al. Ataxia and peripheral nerve hypomyelination in ADAM22-deficient mice. BMC Neuroscience 2005, 6:33.
34. Sagane K., Ohya Y., Hasegawa Y., Tanaka I. Metalloproteinase-like, disintegrin-like, cysteine-rich proteins MDC2 and MDC3: Novel human cellular disintegrins highly expressed in the brain. The Biochemical Journal 1998, 334(Pt 1):93-98.
35. Sagane K., Yamazaki K., Mizui Y., Tanaka I. Cloning and chromosomal mapping of mouse ADAM11, ADAM22 and ADAM23. Gene 1999, 236(1):79-86.
36. Sagane K., Yasushi Y., Sugimoto H. LGI1 and LGI4 bind to ADAM22, ADAM23 and ADAM11. International Journal of Biological Sciences 2008, 4:387-396.
37. Smith K.M., Gaultier A., Cousin H., Alfandari D., White J.M., DeSimone D.W. The cysteine-rich domain regulates ADAM protease function in vivo. The Journal of Cell Biology 2002, 159:893-902.
38. Sternlicht M.D., Sunnarborg S.W. The ADAM17-amphiregulin-EGFR axis in mammary development and cancer. Journal of Mammary Gland Biology and Neoplasia 2008, 13(2):181-194.
39. Tousseyn T., Jorissen E., Reiss K., Hartmann D. Make stick and cut loose-disintegrin metalloproteases in development and disease. Birth Defects Research. Part C, Embryo Today: Review 2006, 78(1):24-46.
40. Tousseyn T., Thathiah A., Jorissen E., Raemaekers T., Konietzko U., Reiss K., et al. ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase. The Journal of Biological Chemistry 2009, 284(17):11738-11747.
41. Zhu P., Sang Y., Xu R., Zhao J., Li C., Zhao S. The interaction between ADAM22 and 14-3-3beta. Science in China. Series C, Life Sciences 2002, 45(6):577-582.
42. Zhu P., Sang Y., Xu H., Zhao J., Xu R., Sun Y., et al. ADAM22 plays an important role in cell adhesion and spreading with the assistance of 14-3-3. Biochemical and Biophysical Research Communications 2005, 331(4):938-946.